Nicole Paulk, PhD
UCSF, Biochemistry and Biophysics
Engineering technologies for improving human liver gene and cell therapies
For patients seeking treatment for genetic liver diseases, the standard of care can often be invasive (e.g. liver transplantation) and temporary (e.g. enzyme replacement therapy). Gene and cell therapies are attractive alternatives as they can be non-invasive with long-term therapeutic benefits. However, the success of this new generation of translational hepatic therapies are critically dependent on efficiency, efficacy, safety and cost. In the Paulk lab we engineer new technologies to address these needs. We study sexually dimorphic proteomic and transcriptomic human liver signatures pre/post regeneration and viral infection, develop viral genome engineering platforms, design combinatorial gene therapies to improve targeting and reduce costs, and create new human liver mouse models to validate gene and cell therapies in human liver in vivo.
Hosted by Holger Willenbring, MD, PhD
